 By Using the Protege EverfLex Nitinol Stent System II (DURABILITY II) trial was a single-arm trial investigating the efï¬cacy of a single self-expanding nitinol stent in
the treatment of occlusive lesions in the SFA >4 and <
20 cm. Duplex-derived primary patency at 1 year was
77.2% for lesions with a mean length of 8.9 cm.211 The Zilver